Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 700 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Supernus Pharmaceuticals Stock Down 0.4 %

Shares of SUPN stock traded down $0.15 on Wednesday, reaching $39.00. 255,211 shares of the stock were exchanged, compared to its average volume of 331,395. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.69. The stock has a market cap of $2.15 billion, a P/E ratio of 36.45 and a beta of 0.90. The firm has a 50 day moving average of $36.98 and a two-hundred day moving average of $34.32.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.29) earnings per share. On average, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SUPN shares. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They set an “overweight” rating and a $57.00 price objective on the stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SUPN. Bank of Montreal Can grew its holdings in Supernus Pharmaceuticals by 1,508.0% during the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after purchasing an additional 109,088 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at about $1,967,000. Cubist Systematic Strategies LLC grew its stake in shares of Supernus Pharmaceuticals by 98.3% during the second quarter. Cubist Systematic Strategies LLC now owns 79,632 shares of the specialty pharmaceutical company’s stock valued at $2,130,000 after acquiring an additional 39,479 shares in the last quarter. Millennium Management LLC increased its position in shares of Supernus Pharmaceuticals by 395.1% during the second quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock worth $4,316,000 after acquiring an additional 128,743 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Supernus Pharmaceuticals by 7.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company’s stock worth $710,000 after acquiring an additional 1,870 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.